NCT06818097Completed
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
Efficacy Analysis of the Combined Target - Immunotherapy and XELOX Chemotherapy Regimen in the Treatment of Advanced Hepatocellular Carcinoma.
Source: ClinicalTrials.gov · Last updated 20 May 2025
Brief summary (registry, in English)
In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public. Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are suitable for surgery at first diagnosis. So systemic anti-tumor therapy is crucial for advanced HCC. Small-molecule targeted drugs like lenvatinib and sorafenib are NCCN-recommended first-line drugs for advanced HCC. The combination of targeted drugs and immune checkpoint inhibitors can prolong overall survival with good safety. The "2024 Guidelines for HCC Diagnosis and Treatment" shows that platinum-containing chemotherapy is a preferred systemic treatment for advanced HCC. However, in real-world practice, the efficacy and safety of the combination of targeted-immunotherapy and chemotherapy regimen for advanced HCC remain unclear.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68 (actual)
- First submitted
- 16 Jan 2025
- Start date
- 1 Oct 2021
- Primary completion date
- 1 Apr 2025
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06818097
What you commit to
- Study type: Observational
- Participants enrolled: 68
- From 1 Oct 2021 to the primary completion date, 1 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Experienced rupture and bleeding of esophageal or gastric varices within the past six months.
- Imaging examinations reveal cardiac involvement in hepatocellular carcinoma.
Other
- Imaging findings indicate the presence of main portal vein invasion in hepatocellular carcinoma.
- Imaging results show inferior vena cava involvement in hepatocellular carcinoma.
- Pregnancy and lactation.
Who the study is looking for
- Be aged 18 years or older and be diagnosed with HCC by histology, cytology, or imaging studies.
- Have HCC with a clinical stage corresponding to Barcelona Clinic Liver Cancer (BCLC) stage C.
- Have not undergone systemic treatment previously, and initially receive the targeted - immunotherapy combined with XELOX chemotherapy regimen (lenvatinib + Sintilimab or Camrelizumab or Tislelizumab + Capecitabine + Oxaliplatin) upon the diagnosis of HCC.
- Have a liver function classified as Child - Pugh grade A or B.
- Have an ECOG PS score of 0 or 1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sen Memorial Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.